To include your compound in the COVID-19 Resource Center, submit it here.

Tesaro slips on slow Zejula uptake

Tesaro Inc. (NASDAQ:TSRO) lost $13.64 (12%) to $98.44 on Wednesday after reporting lighter-than-expected 3Q sales for ovarian cancer drug Zejula niraparib. Tesaro released its earnings after market

Read the full 270 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE